The purpose of this study was to evaluate the short-term efficacy of topical capsaicin treatment in patients severely affected by fibromyalgia. One hundred and thirty fibromyalgia patients were randomly divided into two groups. The control group, 56 women and 4 men who continued their medical treatment, and the capsaicin group, 70 women who apart from continuing their medical treatment, also underwent topical capsaicin 0.075 % 3 times daily for 6 weeks. At the beginning of the program, there were no significant differences between the two groups in any of the analyzed parameters. At the end of the treatment, there were significant improvements in the capsaicin group in the myalgic score (5.21 vs 3.8, p = 0.02) and global subjective improvement (22.8 vs 5 %, p = 0.001). Six weeks after the end of the treatment, the experimental group showed significant differences in Visual Analogue Scale of depression (5.63 vs 7.35, p = 0.02), Fibromyalgia Impact Questionnaire (67.89 vs 77.7, p = 0.02), role limitations due to emotional problems (36.17 vs 17.2, p = 0.05), Fatigue Severity Scale (6.2 vs 6.6, p = 0.04), myalgic score (3.94 vs 2.66, p = 0.02) and pressure pain threshold (79.25 vs 56.71, p = 0.004). In conclusion, patients severely affected by fibromyalgia can obtain short-term improvements following topical capsaicin 0.075 % treatment three times daily for 6 weeks.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of FM: report of the Multicenter Criteria Committee. Arthritis Rheum 33(2):160–172
Staud R (2002) Evidence of involvement of central neural mechanisms in generating fibromyalgia pain (review). Curr Rheumatol Rep 4(4):299–305
Herpfer I, Lieb K (2003) Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 4(2):56–63
Russell IJ, Orr MD, Littman B et al (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37(11):1593–1601
Nolano M, Simone DA, Wendelschafer-Crabb G et al (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. Pain 81(1–2):135–145
Morgenlander JC, Hurwitz BJ, Massey EW (1990) Capsaicin for the treatment of pain in Guillain-Barré syndrome. Ann Neurol 28(2):199
Mason L, Moore RA, Derry S et al (2004) Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 328(7446):991
Vargas A, Vargas A, Hernandez-Paz R et al (2006) Sphygmomanometry-evoked allodynia-a simple bedside test indicative of fibromyalgia: a multicentre developmental study. J Clin Rheumatol 12(6):272–274
Lázaro C, Bosch F, Torrubia R et al (1994) The development of a Spanish questionnaire for assessing pain: preliminary data concerning reliability and validity. Eur J Psychol Assess 10(2):145–151
Tan G, Jensen MP, Thornby JI et al (2004) Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 5(2):133–137
Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1124
Royuela Rico A, Macías Fernández JA (1997) Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 9(2):81–94
Beck AT, Brown G, Epstein N et al (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol 56:893–897
Beck AT, Ward CH, Mendelson M et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571
García Campayo J, Rodero B, Alda M et al (2008) Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia. Med Clín 131(13):487–492
Rivera J, Gonzalez T (2004) The Fibromyalgia impact questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 22(5):554–560
Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1(1):20
Harwood RH, Rogers A, Dickinson E et al (1994) Measuring handicap: the London handicap scale a new outcome measure for chronic disease. Qual Health Care 3(1):11–16
Staud R (2010) Is it all central sensitization? Role of peripheral tissue nociception in chronic musculoskeletal pain. Cur Rheumatol Rep 12(6):448–454
Hong CZ, Hsueh TC (1996) Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 77(11):1161–1166
Morris V, Cruwys S, Kidd B (1998) Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett 250(3):205–207
McCarty DJ, Csuka M, McCarthy G et al (1994) Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 23(Suppl 3):41–47
Acasuso Diaz M, Collantes Estevez E, Jordi Reus S (1998) Capsaicina versus ketoprofen en tratamiento tópico de la fibromialgia primaria. XXIV Congreso Nacional de la Sociedad Española de Reumatología, Cádiz, Junio
Ebner K, Muigg P, Singewald G et al (2008) Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann NY Acad Sci 1144:61–73
Wallace DJ, Linker-Israeli M, Hallegua D et al (2001) Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 40(7):743–749
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Casanueva, B., Rodero, B., Quintial, C. et al. Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. Rheumatol Int 33, 2665–2670 (2013). https://doi.org/10.1007/s00296-012-2490-5
- Capsaicin therapy
- Chronic pain
- Clinical assessment